---
layout: default
title: Buclizine
parent: 僅模型預測 (L5)
nav_order: 79
evidence_level: L5
indication_count: 0
---

# Buclizine
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Buclizine: Repurposing Assessment — Insufficient Data to Proceed

## One-Sentence Summary

Buclizine (DB00354) is a DrugBank-registered compound for which the current evidence pack contains no original indication records and no TxGNN-predicted new indications.
A full repurposing evaluation cannot be completed at this stage.
**Recommended Decision: Hold** — critical data must be resolved before further assessment.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in current data |
| Predicted New Indication | No predictions generated |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 — no actual studies; prediction pipeline did not produce results |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |

---

## Why No Prediction Is Available

The TxGNN prediction pipeline returned an empty result set for Buclizine. Two plausible causes are:

1. **DrugBank mapping gap**: If Buclizine (DB00354) could not be confidently placed in the TxGNN knowledge graph — for example, due to missing or ambiguous node embeddings — the model would produce no scored candidates.
2. **Missing MOA anchor**: Without a confirmed mechanism of action, the knowledge-graph traversal has no reliable starting edges from which to propagate repurposing signals.

In addition, no original indication text is present in the evidence pack. Without knowing what Buclizine was approved to treat, it is not possible to contextualise any future prediction or assess mechanistic plausibility.

> Currently, detailed mechanism of action data is not available. Based on known information, Buclizine belongs to the piperazine-class antihistamines; however, this has not been confirmed by the DrugBank API query and should not be relied upon for clinical decision-making without verification.

---

## South Africa Market Information

Buclizine holds **no SAHPRA registrations** and is currently **not marketed** in South Africa. There are no approved dosage forms, approved indications, or registration numbers to report.

---

## Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The evidence pack is structurally incomplete — the TxGNN model produced no predicted indications, original indication data is absent, and mechanism of action information was not retrieved. A repurposing evaluation cannot be conducted without these foundations.

**To proceed, the following is needed:**

- **TxGNN re-run**: Confirm that DB00354 maps to a valid knowledge-graph node; re-execute prediction and verify that `predicted_indications` is populated
- **MOA retrieval**: Query the DrugBank API for Buclizine's pharmacodynamics, targets, and mechanism of action (currently flagged as a High-severity data gap)
- **Original indication data**: Retrieve approved indication text from SAHPRA, the British National Formulary, or WHO INN records to establish the repurposing baseline
- **Regulatory PI review**: Download the SAHPRA-approved Professional Information (or equivalent international label) to populate warnings, contraindications, and drug-interaction fields (currently flagged as a Blocking data gap)
- **South Africa market feasibility**: Given zero current SAHPRA registrations, a new registration pathway would be required if any repurposing indication were ultimately supported — this regulatory timeline should be scoped early

---

*This report was generated from Evidence Pack `TW-DB00354-multi` (v4, data cut-off 2026-04-04). Results are for research reference only and do not constitute medical advice. All repurposing candidates require clinical validation before application.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

